Jeffrey S. Mathiesen, insider at Helius Medical Technologies

Jeffrey S. Mathiesen Insider Information

Jeff is an accomplished senior executive and director of public and privately held companies with broad experience in the biopharmaceutical, medical device, semiconductor capital equipment and water filtration markets.  Mr. Mathiesen has served as Director and Audit Committee Chair of Sun BioPharma, Inc. (OTCMKTS: SNBP), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, since 2015, and was appointed Vice Chair and Lead Independent Director in March 2020. Mr. Mathiesen has also served as Director and Audit Committee Chair of NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a publicly traded medical technology company providing neuromodulation continuous EEG monitoring and treatment solutions for patients suffering from epilepsy and other nerve related disorders, since 2017, and eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020. Mr. Mathiesen most recently served as CFO and Advisor to the CEO of Teewinot Life Sciences Corporation, a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. He previously served as the CFO of Gemphire Therapeutics Inc., a publicly-held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, and as CFO of Sunshine Heart, Inc., a publicly-held early-stage medical device company, both of which completed successful IPOs and follow-on equity offerings. Mr. Mathiesen has held executive and financial management positions with private and publicly traded companies dating back to 1987.  He began his career at Deloitte & Touche LLP. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

What is Jeffrey S. Mathiesen's net worth?

The estimated net worth of Jeffrey S. Mathiesen is at least $2,081.31 as of August 10th, 2016. Mr. Mathiesen owns 3,927 shares of Helius Medical Technologies stock worth more than $2,081 as of August 17th. This net worth approximation does not reflect any other assets that Mr. Mathiesen may own. Additionally, Mr. Mathiesen receives an annual salary of $264,330.00 as CFO at Helius Medical Technologies. Learn More about Jeffrey S. Mathiesen's net worth.

How old is Jeffrey S. Mathiesen?

Mr. Mathiesen is currently 61 years old. There are 3 older executives and no younger executives at Helius Medical Technologies. Learn More on Jeffrey S. Mathiesen's age.

What is Jeffrey S. Mathiesen's salary?

As the CFO of Helius Medical Technologies, Inc., Mr. Mathiesen earns $264,330.00 per year. The highest earning executive at Helius Medical Technologies is Mr. Dane Carl Andreeff, Pres, CEO & Director, who commands a salary of $289,400.00 per year. Learn More on Jeffrey S. Mathiesen's salary.

How do I contact Jeffrey S. Mathiesen?

The corporate mailing address for Mr. Mathiesen and other Helius Medical Technologies executives is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. Helius Medical Technologies can also be reached via phone at (215) 944-6100 and via email at [email protected] Learn More on Jeffrey S. Mathiesen's contact information.

Has Jeffrey S. Mathiesen been buying or selling shares of Helius Medical Technologies?

Jeffrey S. Mathiesen has not been actively trading shares of Helius Medical Technologies over the course of the past ninety days. Most recently, on Friday, December 17th, Jeffrey S. Mathiesen bought 3,000 shares of Helius Medical Technologies stock. The stock was acquired at an average cost of $5.31 per share, with a total value of $15,930.00. Learn More on Jeffrey S. Mathiesen's trading history.

Who are Helius Medical Technologies' active insiders?

Helius Medical Technologies' insider roster includes Dane Andreeff (CEO), and Jeffrey Mathiesen (CFO). Learn More on Helius Medical Technologies' active insiders.

Are insiders buying or selling shares of Helius Medical Technologies?

In the last twelve months, Helius Medical Technologies insiders bought shares 3 times. They purchased a total of 45,600 shares worth more than $342,705.00. The most recent insider tranaction occured on December, 17th when CFO Jeffrey S Mathiesen bought 3,000 shares worth more than $15,930.00. Insiders at Helius Medical Technologies own 11.2 % of the company. Learn More about insider trades at Helius Medical Technologies.

Information on this page was last updated on 12/17/2021.

Jeffrey S. Mathiesen Insider Trading History at Helius Medical Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2021Buy3,000$5.31$15,930.00View SEC Filing Icon  
See Full Table

Jeffrey S. Mathiesen Buying and Selling Activity at Helius Medical Technologies

This chart shows Jeffrey S Mathiesen's buying and selling at Helius Medical Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Helius Medical Technologies Company Overview

Helius Medical Technologies logo
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $0.53
Low: $0.50
High: $0.55

50 Day Range

MA: $1.17
Low: $0.48
High: $2.00

2 Week Range

Now: $0.53
Low: $0.45
High: $15.68


5,986,731 shs

Average Volume

6,209,174 shs

Market Capitalization

$2.01 million

P/E Ratio


Dividend Yield